Undetected isoniazid resistance leads to rifampin-resistant tuberculosis

This prospective study in Vietnam demonstrates that undetected isoniazid resistance in rifampin-susceptible tuberculosis patients drastically increases the risk of acquiring rifampin resistance by approximately 100-fold, suggesting that routine isoniazid susceptibility testing could significantly reduce the future burden of rifampin-resistant TB.

The Gist

The Big Picture: A "Silent" Weakness

Imagine tuberculosis (TB) as a fortress under attack by a team of four soldiers (the standard four-drug treatment). The most famous soldier is Rifampin, the heavy artillery that usually wins the battle. However, before Rifampin even arrives, the enemy often has a secret weakness: Isoniazid resistance.

Currently, the most common test used to find TB (called Xpert) is like a metal detector that only looks for Rifampin. If the fortress is strong against Rifampin, the test sounds an alarm. But if the fortress is only weak against Isoniazid (the other soldiers), the metal detector stays silent. The doctors think, "Everything is fine," and they send in the standard four-soldier team.

The Problem: Because the test missed the Isoniazid weakness, the team sends in a soldier (Isoniazid) who is useless against this specific enemy. The enemy realizes, "Hey, one of your soldiers is a dud!" and starts building a shield against the only soldier left who can actually hurt them: Rifampin.

What the Researchers Did

The researchers in Vietnam set up a massive surveillance net. They collected sputum (spit) samples from over 33,000 people diagnosed with TB. They didn't just look at the initial diagnosis; they waited to see who got sick again (recurrence).

They used a high-tech "genetic fingerprinting" tool (Whole-Genome Sequencing) to solve a mystery:

1. Did the patient get sick again because the original bacteria survived and evolved? (Acquired Resistance)
2. Or did they catch a brand new, different strain of TB from someone else? (Reinfection)

The Shocking Discovery

The results were like finding a smoking gun.

• The Risk: If a patient had the "silent" Isoniazid resistance that the standard test missed, and they were treated with the standard drugs, their risk of developing resistance to the heavy artillery (Rifampin) jumped by over 100 times.
• The Numbers: Out of the people who developed new Rifampin resistance, 96% had started with that undetected Isoniazid weakness.
• The Analogy: It's like trying to put out a fire with a hose that has a hole in it. The water (Isoniazid) doesn't work, so the fire (bacteria) gets stronger and eventually burns through the only remaining fire extinguisher (Rifampin).

The "Double Trouble" Effect

The study also found that if the bacteria were resistant to other backup soldiers (Pyrazinamide or Ethambutol) in addition to Isoniazid, the risk of the bacteria learning to resist Rifampin went up even higher. It's like the enemy having shields against three different weapons, leaving them completely free to build a shield against the fourth.

The Solution: A Better Metal Detector

The researchers ran a computer simulation to see what would happen if Vietnam changed its strategy.

• Current Strategy: Only test for Rifampin resistance.
• Proposed Strategy: Test for both Rifampin and Isoniazid resistance right at the start.

The Result: If they switched to testing for both drugs and treated patients correctly based on those results, the number of new, hard-to-treat Rifampin-resistant TB cases could drop by nearly half (46%) over the next 10 years.

Even if they only caught 20% of these cases, the number of new resistant TB cases would still drop significantly. The study suggests that catching this "silent" weakness early is the key to stopping the evolution of super-resistant TB.

Summary in One Sentence

This study proves that missing a hidden weakness in TB bacteria (Isoniazid resistance) because our current tests don't look for it is the main reason patients develop the much deadlier, drug-resistant form of TB, but fixing our tests to catch this weakness early could prevent nearly half of these future cases.

Technical Summary

Technical Summary: Undetected Isoniazid Resistance Leads to Rifampin-Resistant Tuberculosis

Problem Statement
Isoniazid resistance (HR) is the most prevalent form of drug-resistant tuberculosis (TB) globally. Current World Health Organization (WHO) recommended molecular diagnostics, such as Xpert MTB/RIF, prioritize the detection of rifampin resistance (RR) but often fail to detect isoniazid resistance in rifampin-susceptible cases. Consequently, patients with isoniazid-resistant, rifampin-susceptible TB (HR-TB) are frequently treated with standard first-line regimens containing isoniazid. This under-treatment creates a selective pressure that risks the de novo emergence of rifampin resistance, potentially converting HR-TB into multidrug-resistant TB (MDR-TB). While transmission of existing RR-TB strains is a known driver of the epidemic, the specific population-level risk of acquiring rifampin resistance due to undetected pre-existing isoniazid resistance has not been precisely quantified.

Methodology
This prospective observational study was conducted in Ho Chi Minh City, Vietnam, between March 2020 and July 2024. The study design involved:

• Cohort Construction: The researchers collected and archived sputum specimens from 33,843 adults diagnosed with rifampin-susceptible pulmonary TB. From this source population, 1,241 participants were enrolled into three sub-cohorts based on outcomes: no recurrence, rifampin-susceptible recurrence, and rifampin-resistant recurrence.
• Genomic Analysis: Whole-genome sequencing (WGS) was performed on paired isolates (index and recurrence) to distinguish between relapse (acquired resistance, defined as ≤12 single nucleotide polymorphism [SNP] differences) and reinfection (>12 SNP differences).
• Statistical Modeling: To estimate the causal effect of pre-existing isoniazid resistance on the acquisition of rifampin resistance, the authors employed inverse probability of treatment weighting (IPTW) to adjust for confounding variables (age, sex, diabetes, HIV status, and M. tuberculosis lineage). Sampling weights were derived from national TB program notification data to reflect population-level risks.
• Epidemiological Projection: A deterministic compartmental transmission model, calibrated to Vietnamese TB incidence data, was used to project the impact of universal HR-TB diagnosis and appropriate treatment on RR-TB incidence over a 10-year period (2025–2035).

Key Results

• Incidence of Acquired Resistance: Among 873 participants with analyzable data, 51 (5.8%) acquired rifampin resistance. Of these, 49 (96.1%) had undetected isoniazid resistance in their index isolate.
• Risk Quantification: After weighting for sampling probability and confounding, the risk of acquiring rifampin resistance was 2.98% (95% CI 2.08–4.50) for participants with pre-existing isoniazid resistance, compared to 0.03% (95% CI 0.00–0.08) for those without. This corresponds to a risk ratio of 105.42 (95% CI 33.43–309.69).
• Population Attributable Fraction (PAF): The PAF was estimated at 95% (95% CI 87–98), indicating that nearly all acquired rifampin resistance in this population arose from the treatment of undetected HR-TB with first-line therapy.
• Impact of Companion Drugs: The risk of acquiring rifampin resistance increased significantly when isoniazid resistance was accompanied by resistance to companion drugs. The risk rose from 1.98% (isoniazid monoresistance) to 13.10% when pyrazinamide or ethambutol resistance was also present.
• Modeling Projections: The transmission model projected that without intervention, RR-TB incidence in Vietnam would be 7.0 per 100,000 by 2035. Implementing universal isoniazid susceptibility testing and appropriate treatment starting in 2025 was projected to reduce RR-TB incidence by 46% (95% UI 35–61) by 2035. Even in settings with lower HR-TB prevalence (5%), a reduction of 26% was projected.

Significance and Claims
The authors claim that undetected, under-treated HR-TB confers a greater than 100-fold increased risk of acquiring rifampin resistance. They argue that current diagnostic algorithms relying solely on rifampin detection are insufficient because they fail to identify the primary evolutionary precursor to RR-TB.

The study posits that the "near-necessary precondition" for de novo rifampin resistance under modern programmatic conditions is undetected isoniazid resistance. The authors conclude that expanding drug susceptibility testing to include isoniazid at the time of initial TB diagnosis, combined with effective HR-TB treatment regimens (such as the addition of levofloxacin, pending further evidence), could substantially reduce the global burden of RR-TB. They emphasize that their findings are robust across varying prevalence settings and suggest that the evolutionary pattern of resistance observed in this population reflects a broader biological mechanism relevant to global TB control.